About
Oligomerix is a clinical-stage biotechnology company developing oral small molecule inhibitors targeting protein aggregation for the treatment of Alzheimer's disease and rare neurodegenerative tauopathies.
Explore Oligomerix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.